Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448345 | 0.86 | DGAT1 (0.41) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL21199139 | 0.81 | DGAT1 (0.46) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL3447654 | 0.79 | ALDH1A1 (0.44) | HIF1A | |
| SCHEMBL3344583 | 0.77 | OPRK1 (0.42) | — | |
| SCHEMBL29858041 | 0.77 | PDGFRB (0.50) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL21199260 | 0.77 | DGAT1 (0.44) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL359635 | 0.77 | PDGFRB (0.50) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL19806132 | 0.75 | DGAT1 (0.44) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL30963226 | 0.75 | DGAT1 (0.44) | DGAT1PDGFRBKDRGSK3AGSK3B | |
| SCHEMBL17464375 | 0.75 | DGAT1 (0.44) | DGAT1PDGFRBKDRGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | DGAT1 3787/4885PDGFRB 2785/4885KDR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.